Bioventix Announcements

TR-1: Notification of major interest in shares.

To download this report as a PDF file click here.

TR-1: Notification of major interest in shares.

(more…)

The Annual General Meeting of Bioventix Plc (the “Company”) will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on Thursday 6 December 2018 commencing at 2.00pm.

(more…)

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2018. Click here for pdf version.

Highlights:

• Revenue up 21% to £8.8 million
• Profit before tax up 19% to £6.9 million
• Cash up £0.8 million to £7.0 million
• Second interim dividend of 36p per share (2017: 31p)
• Special dividend of 55p per share (2017: 40p)

(more…)

Bioventix plc
(“Bioventix” or “the Company”)
Notice of Results and Notice of AGM

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it will release its preliminary results for the year ended 30 June 2018 on 8 October 2018.
The Company’s Annual General Meeting will be held on Thursday 6 December at 2.00p.m at Farnham Castle, Castle Street, Farnham, Surrey, GU9 0AG.

(more…)

TR-1: Notification of major interest in shares.

(more…)

TR-1: Notification of major interest in shares. (more…)

Unaudited interim results for the six months ended 31st December 2017. (more…)

TR-1: Notification of major interest in shares. (more…)

Bioventix plc

(“Bioventix” or the “Company”)

Result of AGM

Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly passed.

(more…)